• 1
    Sant M, Aareleid T, Berrino F, Bielska LM, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Ann Oncol 2003; 14( Suppl 5): v61v118.
  • 2
    Levi F, Te V-C, Randimbison L, La Vecchia C. Cancer risk in women with previous breast cancer. Ann Oncol 2003; 14: 713.
  • 3
    Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 2001; 92: 18.
  • 4
    Evans HS, Lewis CM, Robinson D, Bell C, Møller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 2001; 84: 43540.
  • 5
    Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden 1958–1996. Int J Cancer 2001; 93: 15561.
  • 6
    Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Lê MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 2000; 61: 18395.
  • 7
    Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997; 8: 76470.
  • 8
    Buiatti E, Crocetti E, Acciai S, Gafà L, Falcini F, Milandri C, La Rosa M. Incidence of second primary cancers in three Italian population-based Cancer Registries. Eur J Cancer 1997; 33: 182934.
  • 9
    Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary neoplasms following breast cancer in Saarland, Germany, 1968–1987. Eur J Cancer 1993; 29A: 14104.
  • 10
    Murakami H, Hiyama T, Hanai A, Fujimoto I. Second primary cancers following female breast cancer in Osaka, Japan—a population-based cohort study. Jpn J Clin Oncol 1987; 17: 293302.
  • 11
    Teppo L, Pukkala E, Saxén E. Multiple cancer—an epidemiologic exercise in Finland. J Natl Cancer Inst 1985; 75: 20717.
  • 12
    Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985; 68: 99112.
  • 13
    Ewertz M, Mouridsen HT. Second cancer following cancer of the female breast in Denmark, 1943–80. Natl Cancer Inst Monogr 1985; 68: 3259.
  • 14
    Curtis RE, Hankey BF, Myers MH, Young JL,Jr. The risk of leukemia associated with the first course of cancer treatment: an analysis of the surveillance, epidemiology and end results program experience. J Natl Cancer Inst 1984; 72: 53144.
  • 15
    Adami H-O, Bergkvist L, Krusemo U, Persson I. Breast cancer as a risk factor for other primary malignant diseases. A nation-wide cohort study. J Natl Cancer Inst 1984; 73: 104955.
  • 16
    Muir CS, Percy C. Classification and coding for neoplasms. In: JensenOM, ParkinDM, MacLennanR, MuirCS, SkeetRG, eds. Cancer registration: principles and methods. IARC Scientific publication no. 95. Lyon: IARC, 1991; 6481.
  • 17
    Whelan SL. Classification and coding. In: ParkinDM, WhelanSL, FerlayJ, TeppoL, ThomasDB, eds. Cancer incidence in five continents, vol. VIII. Lyon: IARC, 2003. 3541.
  • 18
    Mansfield CM, Krishnan L, Komarnicky L, Ayyangar KM, Kramer CA. A review of the role of radiation therapy in the treatment of patients with breast cancer. Sem Oncol 1991; 18: 52535.
  • 19
    Roychoudhuri R, Evans H, Robinson D, Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004; 91: 86872.
  • 20
    Neugut AI, Robinson E, Lee WC, Murray T, Karwoski K, Kutcher GJ. Lung cancer after radiation therapy for breast cancer. Cancer 1993; 71: 30547.
  • 21
    Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A. Soft tissue sarcoma after treatment for breast cancer—a Swedish population-based study. Eur J Cancer 1998; 34: 206875.
  • 22
    Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, Hamre M. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52: 12317.
  • 23
    Boice JD,Jr, Land CE, Preston DL. Ionizing radiation. In: SchottenfeldD, FraumeniJF,Jr, eds. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996. 31954.
  • 24
    Huang J, Walker R, Groome PG, Shelley W, Mackillop WJ. Risk of thyroid carcinoma in a female population after radiotherapy for breast carcinoma. Cancer 2001; 92: 14118.
  • 25
    Ron E. Thyroid cancer. In: SchottenfeldD, FraumeniJF,Jr, eds. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996. 100021.
  • 26
    Negri E, Dal Maso L, Ron E, La Vecchia C, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Yoshimoto Y, Jin F, Wingren G, Rosaria GM. A pooled analysis of case–control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control 1999; 10: 14355.
  • 27
    Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003; 30: 7408.
  • 28
    Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000; 18: 283642.
  • 29
    Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296300.
  • 30
    Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 1999; 54: 25560.
  • 31
    Matsuyama Y, Tominaga T, Nomura Y, Koyama H, Kimura M, Sano M, Miura S, Takashima S, Mitsuyama S, Ueo H, Ohashi Y. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 2000; 11: 153743.
  • 32
    Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995; 59: 18690.
  • 33
    Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 315.
  • 34
    Grady D, Ernster VL. Endometrial cancer. In: SchottenfeldD, FraumeniJF,Jr. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996. 10589.
  • 35
    Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001; 10: 70513.
  • 36
    Weiss NS, Cook LS, Farrow DC, Rosenblatt KA. Ovarian cancer. In: SchottenfeldD, FraumeniJF,Jr. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996. 104057.
  • 37
    Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91: 13106.
  • 38
    Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 12606.
  • 39
    Armstrong BK, English DR. Cutaneous malignant melanoma. In: SchottenfeldD, FraumeniJF,Jr. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996. 12821312.
  • 40
    Faggiano F, Partanen T, Kogevinas M, Bofetta P. Socioeconomic differences in cancer incidence and mortality. In: KogevinasM, PearceN, SusserM, BofettaP, eds. Social inequalities and cancer. Lyon: International Agency for Research on Cancer, 1997. 65176.
  • 41
    Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 2004; 111: 7924.